Pelabresib,ruxolitinib
morphosys
[]
watch: john o. mascarenhas, md, discusses updates from the phase 2 manifest trial in patients with myelofibrosis. #eha22 #hematology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.